Massive study aims to unlock secrets of rare Cancer-Predisposing gene

NCT ID NCT04541654

Recruiting now Knowledge-focused Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is collecting information and samples from 1,500 people with TP53 gene changes (linked to Li-Fraumeni Syndrome, a condition that raises cancer risk) and their relatives. Researchers want to better understand how these gene variants affect cancer risk and how accurate family history is. No new treatments are being tested; the goal is to gather knowledge to improve future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLONAL HEMATOPOIESIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clonal hematopoiesis hereditary neoplastic syndrome Li-Fraumeni syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLONAL HEMATOPOIESIS HEREDITARY CANCER SYNDROME LI-FRAUMENI SYNDROME MOSAICISM TP53 GENE MUTATION

Contacts and locations

Locations

Boston Children's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States
Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02215, United States
Judy E. Garber
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.